Armata Pharmaceuticals Inc
AMEX:ARMP
Armata Pharmaceuticals Inc
Operating Income
Armata Pharmaceuticals Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Armata Pharmaceuticals Inc
AMEX:ARMP
|
Operating Income
-$42.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-13%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$10.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
Armata Pharmaceuticals Inc
Glance View
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
See Also
What is Armata Pharmaceuticals Inc's Operating Income?
Operating Income
-42.4m
USD
Based on the financial report for Dec 31, 2024, Armata Pharmaceuticals Inc's Operating Income amounts to -42.4m USD.
What is Armata Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-13%
Over the last year, the Operating Income growth was -4%. The average annual Operating Income growth rates for Armata Pharmaceuticals Inc have been -21% over the past three years , -19% over the past five years , and -13% over the past ten years .
You don't have any saved screeners yet